DRL will be permitted to market a 505(j) generic version of Aloxi in the US on September 30, 2018 or earlier under certain circumstances
Switzerland-based pharma company Helsinn Healthcare has entered into a settlement agreement with Dr Reddy’s Laboratories (DRL) to resolve certain patent litigations relating to the former’s drug Aloxi (palonosetron HCl injection) in the US. Aloxi injection is used in adults to help prevent the nausea and vomiting due to chemotherapy.
According to a statement issued by the Swiss drug maker, Aloxi is currently distributed by Helsinn Healthcare’s marketing partner, Eisai in the US.
“As a result of the settlement, DRL will be permitted to market a 505(j) generic version of Aloxi in the US on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential,” the statement said.
Dr Reddy’s and Helsinn are engaged in a legal battle on the patent related issues over Aloxi.
Helsinn had earlier entered into similar agreement with Sandoz.
Comments are closed.